Abstract: FR-OR76
CKD-Associated Pruritus: Prevalence and Association with Quality of Life for Peritoneal Dialysis Patients, International Results from PDOPPS
Session Information
- Managing the Many Facets of Home Dialysis
November 03, 2023 | Location: Room 120, Pennsylvania Convention Center
Abstract Time: 05:15 PM - 05:24 PM
Category: Dialysis
- 802 Dialysis: Home Dialysis and Peritoneal Dialysis
Authors
- Tennankore, Karthik K., Dalhousie University Faculty of Medicine, Halifax, Nova Scotia, Canada
- Perl, Jeffrey, St Michael's Hospital, Toronto, Ontario, Canada
- Pisoni, Ronald L., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
- Johnson, David W., The University of Queensland, Brisbane, Queensland, Australia
- Kanjanabuch, Talerngsak, Division of Nephrology and Center of Excellence in Kidney Metabolic Disorders, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Kawanishi, Hideki, Tsuchiya General Hospital, Hiroshima, Japan
- Kim, Yong-Lim, Kyungpook National University, Daegu, Korea (the Republic of)
- Lambie, Mark, Keele University, Keele, Staffordshire, United Kingdom
- Shen, Jenny I., The Lundquist Institute, Torrance, California, United States
- Cho, Yeoung Jee, The University of Queensland, Brisbane, Queensland, Australia
- Rigatto, Claudio, Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada
- McCullough, Keith, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
Background
Chronic kidney disease associated pruritus (CKD-aP) is associated with morbidity. The prevalence and burden of CKD-aP in peritoneal dialysis (PD) is not well-known. We sought to determine the CKD-aP prevalence, identify factors associated with a high severity of CKD-aP and the impact of CKD-aP on quality of life (QOL) among patients in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).
Methods
We analyzed cross-sectional data on QOL and CKD-aP from PDOPPS patients from Australia, Canada, Japan, New Zealand, Republic of South Korea, Thailand, the UK, and US between 2014-22. CKD-aP severity in the preceding 4 weeks was self-rated by patients using a 5-point Likert scale from 1: “Not at all bothered by itch” to 5: ”Extremely bothered by itch”. Factors associated with CKD-aP 3-5 (moderate to extreme) v. 1-2 were analyzed using logistic regression. Adjusted linear regressions were used to compare CKD-aP and QOL, assessed using the physical and mental component summary scores (PCS and MCS) of the 12-item Short-Form (SF-12) on the same questionnaire.
Results
43% of the 5534 patients reported moderate to extreme itch; ranging from 50% and 49% (Thailand and the UK, respectively), to 32% (the US). Adjusted logistic regression revealed several parameters associated with CKD-aP (Figure 1). MCS and PCS were negatively associated with increasing CKD-aP severity (p < 0.0001).
Conclusion
Worldwide, CKD-aP is highly prevalent among PD patients and associated with poor quality of life. Efforts to better identify and manage CKD-aP for PD patients are urgently needed.
Funding
- Other NIH Support – Amgen Inc (since 1996, founding sponsor) Akebia Therapeutics, Inc. Astellas Pharma Inc. Bard Peripheral Vascular, Inc. Baxter Healthcare Corp Bayer AG & Bayer Yakuhin, Ltd. Cara Therapeutics, Inc. Chugai Pharmaceutical Co., Ltd. GlaxoSmithKline LLC Japanese Society for Peritoneal Dialysis (JSPD) JMS Co., Ltd. Kidney Foundation Japan (KFJ) Kissei Pharmaceutical Co., Ltd. Kyowa Kirin Co., Ltd. (since 1999 for Japan DOPPS) Merck Sharp & Dohme Corp Nikkiso Co., Ltd. ONO Pharmaceutical Co., Ltd. Terumo Corporation Torii Pharmaceutical Co., Ltd. CSL-Vifor, Ltd.